19th Oct 2015 06:53
LONDON (Alliance News) - Avacta Group PLC, which is developing Affirmer biotherapeutics and research reagents, said on Monday that a study undertaken alongside the University of Copenhagen has shown targeted use of Affirmers in genetically-engineered barley can improve disease resistance in the crop.
The research showed that using specific Affirmer technology on the plants reduced the susceptibility of the barley to powdery mildew by around 40%.
Avacta said the results indicate the potential use of its Affirmers technology in treating and diagnosing a wide range of diseases in plants.
"This work is an important further validation of the Affimer platform and we will continue to keep the market updated on any such results that we are able to share," said Avacta Chief Executive Alastair Smith.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Avacta Group